Jubilant HollisterStier nets US government contract to increase activity at its growing facility

2022-05-31

疫苗紧急使用授权

A pharmaceutical contract manufacturer that has been growing its presence in the US has secured itself a sizable contract from the US government. Jubilant HollisterStier, a subsidiary of Singapore-based Jubilant Pharma Limited, has entered into a cooperative agreement for $149.6 million with the Army Contracting Command. The deal is also in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) on behalf of BARDA. The effort, which was funded under the American Rescue Plan, will enable Jubilant HollisterStier to double its injectable filling production capacity at its Spokane, WA manufacturing facility for a total cost $193 million. The project is slated completion in 2025, according to the company. The company has a history of supporting both HHS and the DOD with biodefense and medical countermeasure programs, including production for national preparedness efforts. “Jubilant HollisterStier LLC is committed to making the US pharmaceutical supply chain more resilient with domestic manufacturing facilities and less reliant on foreign suppliers,” Jubilant Pharma CEO Pramod Yadav said in a statement. In 2021 , Jubilant sought to expand its sterile injectable manufacturing capacity at its Spokane site to keep up with the demand surrounding the Covid-19 vaccine Covid-19 vaccine push. The initial $92 million investment is planned to increase manufacturing capacity by 50% with the inclusion of 2,300-square-foot lyophilizers and 50,000 square feet of building space. The upgrades will allow for 400 vials a minute to be filled. Earlier last year, the company also struck a deal with Eli Lilly for the manufacturing of bamlanivimab at the Spokane plant, however, bamlanivimab’s emergency use authorization was revoked by the FDA for the treatment of Covid-19. In 2021, the company announced that it had signed on with Novavax to provide fill-finish services to its vaccine candidate as well.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构